Join researcher and clinician Dr. Nanette Santoro to review the findings of the Skylight 2 study on fezolinentant and her expectations of approval of a 45 mg daily oral dose to treat VMS in women. 

After listening to this podcast, please visit menopauselearning.com to claim your free CME accreditation.